SanegeneBio

SanegeneBio is developing RNA interference (RNAi) therapeutics for unmet clinical needs. RNAi triggers the gene silencing to reduce the protein production of specific targets by leveraging an evolutionarily conserved mechanism. However, the unique properties of RNA have constrained its widespread application as a drug modality. Using their robust siRNA drug discovery platform, LEAD (Ligand and Enhancer Assisted Delivery), SanegeneBio is designing, screening and developing new RNAi molecules with enhanced tissue distribution and safety profiles. This enables SangeneBio to address diverse extrahepatic disease targets and unleash the full potential of RNAi technologies.

Jobs: